4月15日, – 强生公司公布了2025年第一季度的业绩。“强生公司独特且多元化的产品组合在本季度展现出了强大实力,运营销售额的强劲增长进一步增强了我们对2025年业绩指导的信心,”强生公司董事长兼首席执行官Joaquin Duato表示。“本季度,我们凭借包括TREMFYA(用于炎症性肠病)、RYBREVANT联合LAZCLUZE(用于非小细胞肺癌)、OTTAVA软组织手术机器人系统在内的研发...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.